youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
VTRS:NASDAQ
Viatris Inc
$19.04
arrow_downward
-0.86%(-0.17) 1D
$18.91
arrow_downward
-0.66% (-0.13)bedtimeAfter hours
Closed: Oct 30, 3:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for VTRS...
Open
$19.29
High
$19.50
Low
$19.00
Mkt. cap
21.86B
Avg. vol.
9.25M
Volume
8.79M
Dividend
2.52%
Quarterly dividend
$0.12
Ex-dividend date
Aug 21, 2026
52-wk high
$19.50
52-wk low
$9.92
EPS
-$0.36
Beta
0.86
Shares outstanding
1.15B
No. of employees
30K
Open
$19.29
High
$19.50
Low
$19.00
Mkt. cap
21.86B
Avg. vol.
9.25M
Volume
8.79M
Dividend
2.52%
Quarterly dividend
$0.12
Ex-dividend date
Aug 21, 2026
52-wk high
$19.50
52-wk low
$9.92
EPS
-$0.36
Beta
0.86
Shares outstanding
1.15B
No. of employees
30K
News stories
From web sources and news partners
Zacks
·
2 days ago
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
Profile
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community.
Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. In 2026, Viatris ranked 100 on Time Magazine's World's Most Impactful Companies. Wikipedia
About Viatris Inc
CEOScott A. Smith
Employees30K
FoundedNov 16, 2020
HeadquartersCanonsburg, Pennsylvania, United States
SectorPharmaceutical industry
Websiteviatris.com
Analyst ratings
Based on 9 analysts giving stock ratings to VTRS in the past 3 months
Buy
Buy
5
Hold
3
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for VTRS in the last 3 months.
Highest
Current $19.04
$26.00 (+36.59%)
Average
$20.33 (+6.80%)
Lowest
$14.00 (-26.45%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
David Amsellem Piper Sandler | Hold | Reiterated | $14.00 | -26.5% | 10/26/2026 |
Chris Schott J.P. Morgan | Hold | Reiterated | $20.00 | +5.1% | 10/21/2026 |
Glen Santangelo Barclays | Buy | Maintained | $22.00 | +15.6% | 10/15/2026 |
Jason Gerberry Bank of America Securities | Sell | Maintained | $16.00 | -15.9% | 10/12/2026 |
Salveen Richter Goldman Sachs | Hold | Maintained | $20.00 | +5.1% | 10/08/2026 |
Ashwani Verma UBS | Buy | Maintained | $26.00 | +36.6% | 10/05/2026 |
Les Sulewski Oppenheimer | Buy | Initiated | $25.00 | +31.3% | 09/23/2026 |
Unknown Analyst Oppenheimer | Buy | Initiated | $25.00 | +31.3% | 09/23/2026 |
Daniel Clark Leerink Partners | Buy | Initiated | $20.00 | +5.1% | 09/09/2026 |
Jasper Hellweg Argus Research | Buy | Maintained | $20.00 | +5.1% | 09/08/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $17.00 | -10.7% | 03/20/2026 |
Next call in 4 days
Thu, Nov 5, 3:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.64
Revenue / Est. (USD)
- / 3.79B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 3.76B | 3.70B | 3.52B | 3.76B |
Cost of goods sold | 2.26B | 2.21B | 2.14B | 2.19B |
Cost of revenue | 2.26B | 2.21B | 2.14B | 2.19B |
Research and development expenses | 244.80M | 271.20M | 245.80M | 245.20M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 848.50M | 933.40M | 893.40M | 855.00M |
Operating expense | 1.09B | 1.20B | 1.14B | 1.10B |
Total operating expenses | 3.36B | 3.42B | 3.28B | 3.29B |
Operating income | 404.60M | 288.20M | 238.60M | 471.50M |
Other non operating income | -135.90M | 44.90M | -1.80M | 14.40M |
EBT including unusual items | -7.90M | -343.00M | -247.30M | -64.00M |
EBT excluding unusual items | 318.70M | 188.00M | 146.20M | 365.40M |
Income tax expense | 120.30M | -2.90M | -423.70M | 54.80M |
Effective tax rate | -1,522.78% | 0.85% | 171.33% | -85.62% |
Other operating expenses | - | - | - | - |
Net income | -128.20M | -340.10M | 176.40M | -118.80M |
Net profit margin | -3.41% | -9.18% | 5.02% | -3.16% |
Earnings per share | 0.67 | 0.57 | 0.59 | 0.69 |
Interest and investment income | - | - | - | - |
Interest expense | -119.60M | -119.60M | -120.10M | -120.70M |
Net interest expenses | -119.60M | -119.60M | -120.10M | -120.70M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 1.09B | 981.10M | 914.70M | 1.14B |
Gain or loss from assets sale | -1.60M | 21.90M | 13.90M | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events